Global & Brazil Cancer Therapeutics Market to 2031

Cancer is a major chronic health concern among Brazil’s elderly population. As reported by the Pan American Health Organization (PAHO), over 30 million Brazilians were aged 60 and above in 2022, accounting for approximately 13% of the population. This number is projected to increase to nearly 50 million by 2030, representing 24% of the total population. With a steadily aging population, Brazil is witnessing a surge in cancer incidence, particularly in cases of breast, prostate, and lung cancers. This demographic shift is expected to significantly increase the demand for effective cancer therapies in the coming years.

Data from GLOBOCAN 2020 shows that Brazil recorded 592,212 cancer cases, with 300,144 in men and 292,098 in women. Among these, breast cancer was one of the most frequently diagnosed types. The Brazilian National Cancer Institute (INCA) estimates that approximately 66,200 new breast cancer cases are identified in women each year. Additionally, colorectal cancer—more prevalent among the elderly—had around 55,102 new cases in 2020, based on GLOBOCAN data.

The Brazilian government has made substantial investments in strengthening the country’s healthcare system, enhancing access to oncology services. Institutions like INCA have been instrumental in advancing cancer care and research. These efforts, combined with a growing focus on early diagnosis and personalized treatments, are driving the growth of Brazil's cancer therapeutics market.